Literature DB >> 2825406

Antigenic variation and lentivirus persistence: variations in envelope gene sequences during EIAV infection resemble changes reported for sequential isolates of HIV.

S L Payne1, F D Fang, C P Liu, B R Dhruva, P Rwambo, C J Issel, R C Montelaro.   

Abstract

The extent and nature of genomic variation among nine antigenically distinct EIAV isolates recovered during sequential clinical episodes from two experimentally infected ponies were examined by restriction fragment analysis and nucleotide sequencing. Only minor variations in restriction enzyme patterns were observed among the viral genomes. In contrast, env gene sequences of four isolates from one pony revealed numerous clustered base substitutions. Divergence in env gene nucleotide and deduced amino acid sequences between pairs of virus isolates ranged from 0.62 to 3.4% env gene mutation rates for isolates recovered during sequential febrile episodes were calculated to be greater than 10(-2) base substitutions per site per year. The degree and nature of env gene variation in EIAV is remarkably similar to the human immunodeficiency virus, suggesting common mechanisms for env gene variation among lentiviruses.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2825406     DOI: 10.1016/0042-6822(87)90124-3

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  47 in total

1.  The surface envelope protein gene region of equine infectious anemia virus is not an important determinant of tropism in vitro.

Authors:  S T Perry; M T Flaherty; M J Kelley; D L Clabough; S R Tronick; L Coggins; L Whetter; C R Lengel; F Fuller
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

2.  In vitro isolation of a neutralization escape mutant of equine infectious anemia virus (EIAV).

Authors:  P M Rwambo; C J Issel; K A Hussain; R C Montelaro
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

3.  Comparison of two host cell range variants of feline immunodeficiency virus.

Authors:  T R Phillips; R L Talbott; C Lamont; S Muir; K Lovelace; J H Elder
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

4.  Characterization of variable regions in the envelope and S3 open reading frame of equine infectious anemia virus.

Authors:  S Alexandersen; S Carpenter
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

5.  Analysis of equine humoral immune responses to the transmembrane envelope glycoprotein (gp45) of equine infectious anemia virus.

Authors:  Y H Chong; J M Ball; C J Issel; R C Montelaro; K E Rushlow
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

6.  Identification of a hypervariable region in the long terminal repeat of equine infectious anemia virus.

Authors:  S Carpenter; S Alexandersen; M J Long; S Perryman; B Chesebro
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

7.  Replication in vitro and in vivo of an equine infectious anemia virus mutant deficient in dUTPase activity.

Authors:  D L Lichtenstein; K E Rushlow; R F Cook; M L Raabe; C J Swardson; G J Kociba; C J Issel; R C Montelaro
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

8.  Proviral sequences detected by polymerase chain reaction in peripheral blood cells of horses with equine infectious anemia lentivirus.

Authors:  K I O'Rourke; M L Besola; T C McGuire
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

9.  Major histocompatibility complex-restricted CD8+ cytotoxic T lymphocytes from horses with equine infectious anemia virus recognize Env and Gag/PR proteins.

Authors:  T C McGuire; D B Tumas; K M Byrne; M T Hines; S R Leib; A L Brassfield; K I O'Rourke; L E Perryman
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

10.  Genomic quasispecies associated with the initiation of infection and disease in ponies experimentally infected with equine infectious anemia virus.

Authors:  D L Lichtenstein; C J Issel; R C Montelaro
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.